Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.

ABSTRACT:

Background and objective

Large clinical trials have confirmed the long-term efficacy of inhaled corticosteroid/long-acting β₂-agonist combinations in patients with chronic obstructive pulmonary disease (COPD). It was hypothesized that significant treatment effects would already be present within 3 months after the initiation of treatment across a range of clinical outcomes, irrespective of COPD severity.

Methods

Post hoc analysis of 3-month post-randomization outcomes, including exacerbation rates, dropouts, symptoms, reliever use, and lung function, from three studies with similar inclusion criteria of moderate-to-very-severe COPD. Patients (n=1,571) were treated with budesonide/formoterol (B/F) 320/9 μg or placebo, twice daily; in one study, tiotropium 18 μg onc

SUBMITTER: Calverley PM 

PROVIDER: S-EPMC5182036 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature